A method for automated pathogenic content estimation with application to rheumatoid arthritis.

Area of Science:

• Microbiome research
• Mammalian gut-intestinal microbiome analysis
• Metagenomics

Background:

• Mammalian microbiome sequencing advances health and disease understanding.
• Evaluating drug and disease impact on the gut-intestinal (GI) microbiome is crucial for assessing disease progression and therapy effects.
• Current metagenomic analyses using alpha-diversity or Firmicutes/Bacteroides ratios offer limited interpretability regarding microbial composition evolution, especially with incomplete species knowledge.

Purpose of the Study:

• To develop a novel, quantitative method for evaluating microbiome global composition.
• To automatically annotate pathogenic genera and statistically assess the frequency of harmless versus harmful organisms.
• To provide additional insights into treatment impacts on the GI microbiome, particularly for rheumatoid arthritis (RA).

Main Methods:

• Automatic annotation of pathogenic bacterial genera within the microbiome.
• Statistical assessment of the net varied frequency of harmless versus harmful organisms.
• Application to human GI-microbiome data, integrating with existing analytical approaches.

Main Results:

• The proposed method is intuitive, quantitative, and computationally efficient, addressing limitations of incomplete species functional knowledge.
• The analysis provides additional layers of interpretation for microbiome data.
• Demonstrated distinct physiologic effects of Prednisone versus Methotrexate on the GI microbiome in RA patients.

Conclusions:

• The quantitative analysis offers a systemic level of interpretation for microbiome data.
• This approach integrates with existing methods, enhancing understanding of treatment effects.
• The findings have potential for translation into clinically relevant information for RA therapies.